The use of the GnRH analogue buserelin for IVF--does it improve fertility?

What Was Tested

Researchers studied HMG (Human Menopausal Gonadotropin) and Buserelin in this randomized controlled trial publication.

To determine the effect of a short course of the GnRH analogue buserelin and human menopausal gonadotrophin (hMG), for ovarian stimulation in their IVF programme, on reproductive endocrinology and pregnancy rates compared with conventional clomiphene citrate and hMG treatment.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Prospective randomized allocation to one of two ovulation stimulation regimens.

All the women were less than 46 years of age and had normal menstrual cycles.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the HMG (Human Menopausal Gonadotropin) group and the comparison group should start out alike.

The first group (n = 151) was given clomiphene citrate (CC) from days 2-6 of the menstrual cycle and hMG from day 5 onwards (CC/hMG).

The second group (n = 222) was given buserelin from days 1-3 and hMG from day 2 (buserelin/hMG).

What Was Measured

PubMed files the paper under topics including Buserelin, Clomiphene, Estradiol, Fertilization in Vitro, Luteinizing Hormone, Menotropins and Ovarian Follicle.

What This Means in Plain Language

The paper is a randomized study of HMG (Human Menopausal Gonadotropin) and Buserelin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1991 (British journal of obstetrics and gynaecology), a journal based in England.

More context: the HMG (Human Menopausal Gonadotropin) compound page and the Buserelin compound page, all human trials.